Archives
Patient-Derived Gastric Cancer Assembloids: Modeling Tumor–S
2026-05-02
Patient-Derived Gastric Cancer Assembloids: Modeling Tumor–Stroma Interactions
Study Background and Research Question
Gastric cancer remains a leading cause of cancer mortality worldwide, with a five-year survival rate below 10% for advanced cases—despite diverse therapeutic options (source: paper). This poor prognosis is closely linked to the pronounced heterogeneity of gastric tumors and the complex interplay between malignant epithelial cells and their surrounding stroma. Most preclinical models, including traditional three-dimensional organoids, fall short in capturing the diverse cellular microenvironment, especially the role of distinct cancer-associated fibroblasts and stromal cells in modulating drug responses and fostering resistance. The key research question addressed in this study is: Can integrating matched stromal subpopulations with tumor organoids yield an in vitro model that more faithfully recapitulates patient-specific tumor microenvironments and drug responsiveness?Key Innovation from the Reference Study
The pivotal innovation of Shapira-Netanelov et al. lies in the generation of gastric cancer "assembloids"—advanced three-dimensional constructs that co-culture patient-matched epithelial organoids and diverse stromal cell subtypes, all derived from the same primary tumor tissue (source: paper). By tailoring growth conditions and optimizing media to support the survival and interaction of both epithelial and stromal populations, the authors achieve a model system that closely mirrors the heterogeneity and microenvironmental complexity of clinical gastric cancers. This enables unprecedented fidelity in studying cell–cell interactions, tumor progression pathways, and, crucially, patient- and drug-specific variability in therapeutic response.Methods and Experimental Design Insights
The methodology centers on systematic tissue dissociation and parallel expansion of key cell types:- Primary tumor tissues are enzymatically and mechanically dissociated.
- Resulting cells are cultured in specialized media to select for four major subpopulations: epithelial organoids, mesenchymal stem cells, fibroblasts, and endothelial cells.
- Cell identities are confirmed via immunofluorescence staining for lineage-specific markers.
- Matched subpopulations are then recombined in optimized assembloid co-culture media, supporting physiological cell ratios and promoting intricate cell–cell interactions.
- Transcriptomic profiling (RNA-seq) and biomarker analysis verify the retention of key features from the original tumor.
- Drug response is assessed using cell viability assays, comparing responses in assembloids versus monocultures to various therapeutic agents (source: paper).
Protocol Parameters
- cell viability assay | live/dead cell ratio; no fixed unit | assembloid vs. monoculture comparison | enables evaluation of drug-induced cytotoxicity in heterogeneous models | paper
- organoid:stromal cell ratio | variable (patient-specific) | assembloid modeling | reflects in vivo tumor heterogeneity and influences drug responses | paper
- calcium folinate (Leucovorin Calcium) concentration | workflow-recommendation: 10–100 μM | methotrexate rescue, folate metabolism studies | concentrations align with literature protocols for protecting cells from antifolate drugs | workflow_recommendation
- Leucovorin Calcium storage | −20°C | maintains chemical stability for experimental use | aligns with product specification | product_spec
Core Findings and Why They Matter
The assembloid system demonstrated several advantages over traditional monoculture and organoid approaches:- Retention of cellular heterogeneity: The co-culture of matched epithelial and stromal cells produced constructs that robustly expressed both tumor and stromal biomarkers, closely aligning with the parent tumor’s profile (source: paper).
- Enhanced modeling of tumor microenvironment: Transcriptomic analysis revealed higher expression of inflammatory cytokines, extracellular matrix remodeling factors, and genes linked to tumor progression in assembloids than in monocultures.
- Drug response variability: Drug screening illustrated that certain agents lost efficacy in the assembloid context, highlighting the protective or modulatory influence of stromal cells. This is highly relevant for antifolate drug resistance research and for understanding the limitations of conventional cell proliferation assays that lack stromal components.
- Personalized therapeutic implications: The model’s patient-specific construction enables tailored drug screening and the identification of resistance mechanisms that may be masked in simpler systems.
Comparison with Existing Internal Articles
Recent internal resources have anticipated and supported these advances:- Leucovorin Calcium: Empowering Methotrexate Rescue in Assembloid Systems highlights the compound’s utility in advanced assembloid models, emphasizing its solubility, high purity, and relevance for studying drug resistance and tumor–stroma interactions.
- Leucovorin Calcium in Translational Oncology: Mechanistic Advances contextualizes the use of Leucovorin Calcium as a research tool for optimizing methotrexate rescue and cell viability assays in assembloid models, echoing the reference paper’s emphasis on physiologically relevant drug screening.
- Further, Redefining Methotrexate Rescue and Tumor Microenvironment Modeling elaborates on using Leucovorin Calcium to probe antifolate resistance and maintain cell viability in high-complexity cancer models, paralleling the reference study’s goals.
Limitations and Transferability
While the assembloid platform marks a significant step forward, some limitations should be noted:- Scalability and reproducibility: Generating patient-specific assembloids is resource-intensive and may present batch variability, posing challenges for high-throughput drug screening.
- Incomplete recapitulation of immune complexity: Although stromal and endothelial cells are included, immune cell populations—important mediators of drug response—were not systematically incorporated. This may limit the model’s ability to fully reflect in vivo immunomodulation (source: paper).
- Transferability to other tumor types: While the methodology is conceptually adaptable, its effectiveness in modeling the microenvironment of non-gastric cancers requires further validation.